Document
... [Grade A, Level 1A]; and Other classes of antihyperglycemic agents may be used either alone or in combination to attain glycemic targets, with consideration given to the information in Table 1 and Figure 1 [Grade D, Consensus for the order of antihyperglycemic agents listed in Figure 1]. ...
... [Grade A, Level 1A]; and Other classes of antihyperglycemic agents may be used either alone or in combination to attain glycemic targets, with consideration given to the information in Table 1 and Figure 1 [Grade D, Consensus for the order of antihyperglycemic agents listed in Figure 1]. ...
Download CV
... Popik P, Kozela E, Wrobel M, Wozniak KM, Slusher BS. "Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA." Neuropsychopharmacology, 2003, 28(3):457-67 Stoermer D, Liu Q, Hall MR, F ...
... Popik P, Kozela E, Wrobel M, Wozniak KM, Slusher BS. "Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA." Neuropsychopharmacology, 2003, 28(3):457-67 Stoermer D, Liu Q, Hall MR, F ...
Evaluation of different mycobacterial species for drug discovery and
... used for anti-Tb drug high-throughput screening (HTS), and to use this model to identify a novel candidate anti-tubercular drug and its cognate cellular target. A sensitive growth inhibition assay was set up with a GFP-labelled Tb vaccine strain, M. bovis BCG, using standard first and second line an ...
... used for anti-Tb drug high-throughput screening (HTS), and to use this model to identify a novel candidate anti-tubercular drug and its cognate cellular target. A sensitive growth inhibition assay was set up with a GFP-labelled Tb vaccine strain, M. bovis BCG, using standard first and second line an ...
In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors from
... al., 1995). It is unlikely that this would be a property of releasing agents, assuming that they produce depolarizationindependent release of 5-HT. 4) Because both reuptake inhibitors and releasing agents such as fenfluramine bind to the 5-HT carrier, pretreatment with reuptake inhibitors can attenu ...
... al., 1995). It is unlikely that this would be a property of releasing agents, assuming that they produce depolarizationindependent release of 5-HT. 4) Because both reuptake inhibitors and releasing agents such as fenfluramine bind to the 5-HT carrier, pretreatment with reuptake inhibitors can attenu ...
Report on the Deliberation Results August 25, 2009 Evaluation and
... Incretins including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are gastrointestinal hormones, are peptide hormones released in active forms by the intestine in response to meal ingestion. When blood glucose concentrations are elevated, GLP-1 and GIP ...
... Incretins including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are gastrointestinal hormones, are peptide hormones released in active forms by the intestine in response to meal ingestion. When blood glucose concentrations are elevated, GLP-1 and GIP ...
the PDF
... Donepezil + memantine (ADS-8704, Arimenda; Adamas Pharmaceuticals), a once-daily fixed dose combination extended release formulation, is currently tested in Phase II clinical trials. In May 2012, the FDA approved Phase III studies in an end-of-Phase II meeting. First clinical results were presented ...
... Donepezil + memantine (ADS-8704, Arimenda; Adamas Pharmaceuticals), a once-daily fixed dose combination extended release formulation, is currently tested in Phase II clinical trials. In May 2012, the FDA approved Phase III studies in an end-of-Phase II meeting. First clinical results were presented ...
Full-Text PDF
... (FXa) has remained the center of attention in the last decade. In this study, 16 ginsenosides and two sapogenins were isolated, identified and quantified. To determine the inhibitory potential on FXa, the chromogenic substrates method was used. The assay suggested that compounds 5, 13 and 18 were ma ...
... (FXa) has remained the center of attention in the last decade. In this study, 16 ginsenosides and two sapogenins were isolated, identified and quantified. To determine the inhibitory potential on FXa, the chromogenic substrates method was used. The assay suggested that compounds 5, 13 and 18 were ma ...
Model-based Analysis of the Effects of Thioridazine Enantiomers on the... Papillary Action Potential
... to competing prolonging and shortening effects. For (-)-thioridazine using the forward method, only a small degree of ICaL inhibition and no IKr inhibition was determined. Using the inverse method, the IKr inhibition was smaller than that determined for both the racemate and (+)-thioridazine. It was ...
... to competing prolonging and shortening effects. For (-)-thioridazine using the forward method, only a small degree of ICaL inhibition and no IKr inhibition was determined. Using the inverse method, the IKr inhibition was smaller than that determined for both the racemate and (+)-thioridazine. It was ...
BoNT_A Presentation UMass Dartmouth 081029
... MBX 1107 has very little activity in this assay. Compounds MBX 1195, 1340 and 1341 appear to have activity at a single concentration of 80 µM. ...
... MBX 1107 has very little activity in this assay. Compounds MBX 1195, 1340 and 1341 appear to have activity at a single concentration of 80 µM. ...
NIH Public Access - The Scripps Research Institute
... The MAP-rFAAH structure remained as the only crystal structure of FAAH for many years. However, the high levels of expression of the h/rFAAH protein offered a new opportunity to solve structures of the enzyme that would be of great relevance to structure-based drug design. Indeed, as noted above, h/ ...
... The MAP-rFAAH structure remained as the only crystal structure of FAAH for many years. However, the high levels of expression of the h/rFAAH protein offered a new opportunity to solve structures of the enzyme that would be of great relevance to structure-based drug design. Indeed, as noted above, h/ ...
Promega`s P450-GloTM Luminescent Cytochrome
... enzymes. The derivatives are not substrates for luciferase but are converted by different P450 isoenzymes to luciferin (Figure 2), which in turn reacts with luciferase to produce a measurable amount of light that is directly proportional to the P450 activity. A luminogenic substrate is incubated wit ...
... enzymes. The derivatives are not substrates for luciferase but are converted by different P450 isoenzymes to luciferin (Figure 2), which in turn reacts with luciferase to produce a measurable amount of light that is directly proportional to the P450 activity. A luminogenic substrate is incubated wit ...
Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
... Background: Sitagliptin was launched into the UK Market in 2007, as the first member of a new class of oral glucose lowering medications, the Dipetidyl Peptidase 4 inhibitors. Aim: To review the efficacy and safety of sitagliptin and discuss its place in therapy. Method: Expert review using publishe ...
... Background: Sitagliptin was launched into the UK Market in 2007, as the first member of a new class of oral glucose lowering medications, the Dipetidyl Peptidase 4 inhibitors. Aim: To review the efficacy and safety of sitagliptin and discuss its place in therapy. Method: Expert review using publishe ...
Synopsis of Some Recent Tactical Application of Bioisosteres in
... for the mechanism-based HCV NS3 protease inhibitor telaprevir (12).39 The (S)-R-ketoamide in 12 readily racemizes at higher pH and, most notably, in human plasma to afford the(R)diastereomer, which exhibits 30-fold weaker biological activity (Figure 2). The (R)-diastereomer of 12 is the primary meta ...
... for the mechanism-based HCV NS3 protease inhibitor telaprevir (12).39 The (S)-R-ketoamide in 12 readily racemizes at higher pH and, most notably, in human plasma to afford the(R)diastereomer, which exhibits 30-fold weaker biological activity (Figure 2). The (R)-diastereomer of 12 is the primary meta ...
